Evidence map›Paper›PMID 42604482›Full record

ReviewAnnals of nuclear medicine2026

Progress in the application of

Tao Jiang, Zunyu Xiao

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tao JiangDepartment of Nuclear Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.ORCID http://orcid.org/0009-0009-5294-8921
Zunyu XiaoDepartment of Nuclear Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China. fyyxiaozunyu@nbu.edu.cn.ORCID http://orcid.org/0009-0005-4890-7220

Funding

National Natural Science Foundation of China No. 822720560Natural Science Foundation of Ningbo Municipality No. 2024J043Natural Science Foundation of Zhejiang Province No. ZCLKLZ25H1602
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by the limited efficacy of current therapies and an urgent need for novel treatment strategies. Targeted radionuclide therapy (TRT) enables the selective delivery of radionuclides to tumor sites via specific ligands, integrating molecular targeting with cytotoxic radiation. Among these radionuclides,

Indexed as

177Lu225AcPancreatic ductal adenocarcinomaTargeted radionuclide therapyTheranostic

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.